Hypoalbuminemia for the prediction of survival in patients with stage IVB cervical cancer

PLoS One. 2022 Sep 2;17(9):e0273876. doi: 10.1371/journal.pone.0273876. eCollection 2022.

Abstract

We evaluated the prognostic significance of malnutrition in patients with metastatic cervical cancer. In this study, we retrospectively analyzed the cases of 43 patients with stage IVB (FIGO2018) cervical cancer treated at our institute from December 2004 to December 2017. We determined the correlation between clinicopathological characteristics and survival by performing univariate and multivariate analyses. The serum albumin value at diagnosis was used as an index of malnutrition. The median follow-up period was 16.4 months (range, 0.9-91.4 months). On Kaplan-Meier analysis, the 1- and 2-year overall survival (OS) rates for all patients were 61.6% and 48.6%, respectively. The optimal serum albumin for predicting 1-year survival was 3.3 g/dL, as determined by the receiver operating characteristic curve to maximize the area under the curve. The OS of the patients with albumin >3.3 g/dL (n = 28) was significantly better than that of the patients with albumin ≤3.3 g/dL (n = 15) (p = 0.004). The univariate and multivariate analyses revealed that pretreatment serum albumin and mode of primary treatment were significantly associated with survival in patients with stage IVB cervical cancer. Hypoalbuminemia was an unfavorable prognostic factor for patients with metastatic cervical cancer.

MeSH terms

  • Female
  • Humans
  • Hypoalbuminemia* / complications
  • Malnutrition*
  • Prognosis
  • Retrospective Studies
  • Serum Albumin
  • Uterine Cervical Neoplasms* / pathology

Substances

  • Serum Albumin

Grants and funding

The authors received no specific funding for this work.